Humacyte, Inc. (NASDAQ:HUMA) Receives $6.25 Consensus Target Price from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have earned an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $6.25.

A number of analysts have recently weighed in on the stock. TD Cowen reduced their price target on shares of Humacyte from $1.50 to $1.25 and set a “buy” rating for the company in a research note on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research note on Wednesday, July 8th. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Tuesday, April 28th. Wall Street Zen cut Humacyte from a “sell” rating to a “strong sell” rating in a research note on Sunday, July 12th. Finally, HC Wainwright boosted their price target on shares of Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Thursday, June 11th.

Insider Buying and Selling

In other news, insider Shamik J. Parikh sold 45,887 shares of the business’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $0.90, for a total transaction of $41,298.30. Following the sale, the insider directly owned 272,713 shares of the company’s stock, valued at $245,441.70. The trade was a 14.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Dale A. Sander sold 45,887 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the sale, the chief financial officer directly owned 267,213 shares of the company’s stock, valued at approximately $240,491.70. This represents a 14.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Sei Investments Co. purchased a new position in Humacyte during the 1st quarter worth approximately $56,000. R Squared Ltd lifted its holdings in shares of Humacyte by 140.5% in the first quarter. R Squared Ltd now owns 62,911 shares of the company’s stock valued at $38,000 after purchasing an additional 36,758 shares in the last quarter. Private Advisor Group LLC boosted its position in shares of Humacyte by 48.3% in the first quarter. Private Advisor Group LLC now owns 832,799 shares of the company’s stock worth $505,000 after buying an additional 271,222 shares during the period. Wealth Effects LLC boosted its position in shares of Humacyte by 33.6% in the first quarter. Wealth Effects LLC now owns 204,500 shares of the company’s stock worth $124,000 after buying an additional 51,433 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Humacyte by 841.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 70,414 shares of the company’s stock valued at $68,000 after buying an additional 62,931 shares in the last quarter. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Stock Down 0.9%

HUMA opened at $0.64 on Friday. Humacyte has a 12 month low of $0.55 and a 12 month high of $2.76. The company has a debt-to-equity ratio of 5.46, a current ratio of 3.93 and a quick ratio of 3.32. The stock has a market cap of $141.78 million, a P/E ratio of -1.12 and a beta of 2.52. The stock’s 50 day moving average price is $0.93 and its 200 day moving average price is $0.95.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Humacyte had a negative return on equity of 2,914.18% and a negative net margin of 4,836.06%.The company had revenue of $0.49 million during the quarter, compared to analyst estimates of $1.46 million. As a group, research analysts predict that Humacyte will post -0.34 earnings per share for the current year.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.